 |
6 Diseases |  |
3 Trials |
|
3 Trials |  |
98 News |  |
| 12» |
- ||| Enrollment change: Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study (clinicaltrials.gov) - Nov 12, 2024
P2, N=99, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=76 --> 99
- | Journal: Custom Cesium-131 Vicryl Mesh Brachytherapy for Recurrent Anal Cancer: A Report of Two Cases. (Pubmed Central) - Oct 24, 2024
Addressing these high-risk positive margin sites with adjuvant brachytherapy after surgical resection is a good option to deliver a high dose of radiation to the R1 resection site while sparing the adjacent critical organs at risk. Herein, we present a case report of two patients with persistent or recurrent anal cancer
- Inert Brachytherapy Seed Placement by Robotic Bronchoscopy With Cone-beam Computed Tomography Guidance to Simulate Early-stage Lung Cancer Treatment: A Human Cadaveric Feasibility Pilot (San Diego Convention Center, Room 5A-B (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_7412;
The mean D90% of 111 Gy with high conformity index of 1. 1 demonstrates that BT seeds implanted by RB-CBCT can provide adequate radiation to target lesions while limiting irradiation of healthy tissue.
- || Trial completion date, Trial primary completion date: Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study (clinicaltrials.gov) - Jan 5, 2024
P2, N=76, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
1 demonstrates that BT seeds implanted by RB-CBCT can provide adequate radiation to target lesions while limiting irradiation of healthy tissue. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- Long-term outcomes for patients with radiorecurrent prostate cancer treated with salvage combination IMRT and brachytherapy. (Level 1, West Hall; Poster Bd # E18) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_312;
This study helps strengthen the rationale for the use of Brachytherapy-based regimens in the treatment of radiorecurrent prostate cancer. In view of its even steeper radial dose falloff, we are currently exploring the advantages of Cs-131 in these patients.
- || Trial completion date, Trial primary completion date: Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study (clinicaltrials.gov) - Nov 27, 2023
P2, N=76, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
In view of its even steeper radial dose falloff, we are currently exploring the advantages of Cs-131 in these patients. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Journal: Monte Carlo Dosimetric Study of Percutaneous Vertebroplasty and Brachytherapy for the Treatment of Spinal Metastases. (Pubmed Central) - Oct 24, 2023
I-125 and Cs-131 seeds may be useful for large tumors filling the entire VB, and also for the extended tumors invading multiple vertebrae. Beta-emitting bone cement is recommended for tumors located near the SC.
- | Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Journal: Outcomes of Brain Metastases with Suspicious Imaging Undergoing Resection to Evaluate for Radionecrosis vs. Tumor Progression. (Pubmed Central) - Oct 3, 2023
We recommend cautious monitoring of possible progression after radiosurgery, with consideration of resection for continuous progression, as a significant proportion of radiographic progression are ultimately pure RN. Management determined by pathology (observation for RN; additional radiation for confirmed tumor) leads to excellent control.
- | Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Journal: Cesium-131 Low-Dose Rate Interstitial Brachytherapy as a Salvage Re-Irradiation Technique in Treating Cervical and Uterine Cancer Pelvic Recurrence with Prior History of Pelvic Radiation. (Pubmed Central) - Oct 3, 2023
We conclude that cesium-131 LDR interstitial brachytherapy is a promising alternative to pelvic exenteration in selective patient population. Future prospective study is warranted.
- | Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Journal: Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer. (Pubmed Central) - Oct 3, 2023
Long-term patient-reported clinically significant decreases in urinary function and urinary incontinence mean EPIC scores occurred up to 18 months following combined external beam radiation and Cs-131 prostate brachytherapy and returned to baseline at 24 months, while clinically significant decrease in urinary irritability/obstructive mean scores occurred at 9 months and returned to baseline at 12 months. At 42 months follow-up, mean urinary domain scores improved from pre-treatment baseline in 15-30% of patients.
- Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Cesium-131 Low-Dose Rate Interstitial Brachytherapy as a Salvage Re-Irradiation Technique in Treating Cervical and Uterine Cancer Pelvic Recurrence with Prior History of Pelvic Radiation (Hall B2; In Person Only; Screen: 3) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_1849;
Local control rate at 6-months was acceptable with minimum toxicity. Long-term follow up is warranted to validate the efficacy of cesium-131 LDR.
- Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer (Hall B2; In Person Only; Screen: 1) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_1460;
Long-term patient-reported clinically significant decreases in urinary function and urinary incontinence mean EPIC scores occurred up to 18 months following combined external beam radiation and Cs-131 prostate brachytherapy and returned to baseline at 24 months, while clinically significant decrease in urinary irritability/obstructive mean scores occurred at 9 months and returned to baseline at 12 months. At 42 months follow-up, mean urinary domain scores improved from pre-treatment baseline in 15-30% of patients.
- Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Outcomes of Brain Metastases with Suspicious Imaging Undergoing Resection to Evaluate for Radionecrosis vs. Tumor Progression (Hall B2; In Person Only; Screen: 3) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_626;
We recommend cautious monitoring of possible progression after radiosurgery, with consideration of resection for continuous progression, as a significant proportion of radiographic progression are ultimately pure RN. Management determined by pathology (observation for RN; additional radiation for confirmed tumor) leads to excellent control.
- | NN1213 / Novo Nordisk
Trial completion: Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer (clinicaltrials.gov) - Jul 27, 2023
P1, N=30, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Management determined by pathology (observation for RN; additional radiation for confirmed tumor) leads to excellent control. Active, not recruiting --> Completed
- | Proxcelan Cesium-131 (cesium-131) / Perspective Therap
Journal: Safety and efficacy of Cesium-131 brachytherapy for brain tumors. (Pubmed Central) - May 30, 2023
Cs-131 brachytherapy demonstrated a favorable safety and efficacy profile characterized by high rates of local control for all treated pathologies. The concept of brachytherapy has seen a resurgence given the excellent results when Cs-131 is used as a source.
- || Proxcelan Cesium-131 (cesium-131) / IsoRay
Review, Journal: Cesium-131 brachytherapy for the treatment of brain metastases: Current status and future perspectives. (Pubmed Central) - Feb 27, 2023
Further analyses have demonstrated superior cost-effectiveness and quality-of-life improvement ratios of cesium-131 brachytherapy than adjuvant stereotactic radiosurgery. Cesium-131 brachytherapy is a safe and effective post-surgical treatment option for brain metastases with associated clinical and cost-effectiveness benefits in appropriately selected patients.
- |||| Proxcelan Cesium-131 (cesium-131) / IsoRay
Cesium-131 brachytherapy for the treatment of brain metastases: Current status and future perspectives. https://t.co/W74Jy4nL1y (Twitter) - Feb 11, 2023
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Journal: Safety and efficacy of salvage therapy with laser interstitial thermal therapy for malignant meningioma refractory to cesium-131 brachytherapy: illustrative case. (Pubmed Central) - Dec 7, 2022
Cesium-131 brachytherapy is a safe and effective post-surgical treatment option for brain metastases with associated clinical and cost-effectiveness benefits in appropriately selected patients. The use of LITT in combination with brachytherapy remains an option for salvage therapy in patients with recurrent meningioma that provides durable local control of tumor.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Journal: Feasibility of collagen matrix tiles with cesium-131 brachytherapy for use in the treatment of head and neck cancer. (Pubmed Central) - Nov 15, 2022
The use of LITT in combination with brachytherapy remains an option for salvage therapy in patients with recurrent meningioma that provides durable local control of tumor. We present a feasibility and concept cadaveric study using a collagen matrix with Cesium-131 demonstrating preliminary evidence to support its ease of use, decreased time to implantation, and decreased dose delivered to the carotid artery.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific, Avastin (bevacizumab) / Roche
Journal: Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial. (Pubmed Central) - Nov 9, 2022
This pre-commercial trial demonstrated acceptable safety and favorable post-treatment local control and survival. The device has received FDA clearance for use in newly diagnosed malignant and all recurrent intracranial neoplasms.
- Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Permanent carrier-embedded cesium-131 brachytherapy for the salvage treatment of previously irradiated, recurrent brain metastases (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_1104;
P2
Modest correlation between preoperative tumor geometry and implanted tiles with high associated cost suggests a need to optimize planning criteria. A randomized trial of salvage resection with or without Cs131 is ongoing (NCT04690348) to assess the incremental benefit of brachytherapy.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Retrospective data, Journal: Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. (Pubmed Central) - Sep 20, 2022
With > 1.5 years of follow-up, intraoperative brachytherapy with commercially available Cs131 implants was associated with favorable local control and toxicity profiles. Weak correlation between preoperative tumor geometry and implanted tiles highlights a need to optimize planning criteria.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific, TheraSeed (palladium-103) / Theragenics
Journal: Patient-specific dose correction for prostate postimplant evaluation with flexible timing of postimplant imaging. (Pubmed Central) - Sep 8, 2022
The postimplant dose calculation based on the proposed inverse power law for prostate seed implants with edema has improved the accuracy of postimplant dosimetry with accurate and patient-specific dose corrections accounting for prostate size, edema half-life, and postimplant imaging times. Optimal times for postimplant imaging have been accurately determined, and high accuracy of postimplant dose calculation can be achieved for both optimal imaging times and non-optimal imaging times.
- | Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer (clinicaltrials.gov) - Aug 29, 2022
P=N/A, N=0, Withdrawn, Sponsor: Ronald M. Benoit, MD
Optimal times for postimplant imaging have been accurately determined, and high accuracy of postimplant dose calculation can be achieved for both optimal imaging times and non-optimal imaging times. N=100 --> 0 | Trial completion date: Feb 2022 --> Jul 2022 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2022 --> Jul 2022
- Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Toxicity Outcomes at 18 Months for Cs-131 Low-Dose-Rate Prostate Brachytherapy Compared to I-125 and Pd-103 (Henry B. Gonzalez Convention Center, Exhibit Hall 1) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_1534;
The type of source used did not predict for need for catheterization, ED, or GI toxicity at any time point. Cs-131 I-125 Pd-103 P value Mean AUA Score Pretreatment 6.1 5.8 7.8 1.00 1 month 20.1 13.4 19.2 <0.001 7 month 8.8 11.1 11.1 0.968 18 month 8.4 10.0 11.6 1.00
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Review, Journal: The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials. (Pubmed Central) - Jul 30, 2022
Initial data suggest that cesium-131 brachytherapy is safe and effective in primary or metastatic malignant brain tumors. Ongoing trials are evaluating long-term locoregional tumor control and future studies should analyze its role in multimodal systemic tumor management.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Journal: Effect of short-term corticosteroid usage on acute urinary toxicity following Cs-131 prostate brachytherapy. (Pubmed Central) - Jul 9, 2022
Ongoing trials are evaluating long-term locoregional tumor control and future studies should analyze its role in multimodal systemic tumor management. A short course of perioperative low-dose prednisone was associated with less severe worsening in urinary symptoms by the EPIC questionnaire at the 0.5-1.0-month timepoint suggesting some improvement in acute urinary quality of life, although differences did not remain statistically significant at 3 months.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Retrospective data, Journal: Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors. (Pubmed Central) - Jun 22, 2022
P=N/A
Intratarget heterogeneity was greater with Pd-103 and I-125 than Cs-131. Dose fall-off was fastest with Pd-103 followed by I-125 and then Cs-131.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution. (Pubmed Central) - Mar 24, 2022
External beam radiotherapy plus PB is a reasonable treatment approach for UIR patients. Future studies may elucidate which IR patients would benefit from treatment intensification.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Journal: Resection with intraoperative cesium-131 brachytherapy as salvage therapy for recurrent brain tumors. (Pubmed Central) - Jan 26, 2022
Future studies may elucidate which IR patients would benefit from treatment intensification. Cesium-131 brachytherapy resulted in good local control and acceptable rates of symptomatic AREs and surgical complications in this heavily pretreated cohort, and it may be a reasonable salvage adjuvant treatment for this patient population.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Review, Journal: Multimodality durable salvage of recurrent brain metastases refractory to LITT, SRS and immunotherapy with resection and cesium-131 brachytherapy: case report and literature review. (Pubmed Central) - Dec 21, 2021
The patient's disease remained stable through 18 months postoperatively. This case illustrates the range of options available and provides a combination salvage therapy strategy in a select group of locally recurrent patients who have exhausted conventional treatment options.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Review, Journal: Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. (Pubmed Central) - Dec 16, 2021
This case illustrates the range of options available and provides a combination salvage therapy strategy in a select group of locally recurrent patients who have exhausted conventional treatment options. LDR brachytherapy is a convenient, effective, and well-tolerated treatment for prostate cancer.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomy. (Pubmed Central) - Dec 16, 2021
The first reported case of GammaTile intraoperative brachytherapy during awake craniotomy supports the safety and feasibility of this treatment strategy. This case indicates that for patients with tumors adjacent to eloquent cortex, awake craniotomy can allow for custom implantation of intraoperative brachytherapy following maximum safe resection.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck Cancer. (Pubmed Central) - Dec 14, 2021
P1
Among patients with local/regional recurrent HNSCC status-post radiation, surgery + Cs-131 demonstrated acceptable safety with compelling oncologic outcomes, as compared to historic control cohorts. ClinicalTrials.gov, identifiers NCT02794675 and NCT02467738.
- Proxcelan Cesium-131 (cesium-131) / Boston Scientific
[VIRTUAL] Salvage Resection and Intracranial Cesium-131 Brachytherapy for Brain Tumors (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_2189;
ClinicalTrials.gov, identifiers NCT02794675 and NCT02467738. Cesium-131 brachytherapy in this heavily pre-treated cohort resulted in good local control and an acceptable rate of symptomatic adverse radiation effect and toxicity, and may be a reasonable treatment option for this select population.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Comparison of Three Groups of Patients Having Low Dose Rate Prostate Brachytherapy: Prostate-Specific Antigen Failure and Overall Survival. (Pubmed Central) - Oct 30, 2021
The median PSA value at 60 months was 0.11 ng/ml. There were only a few PSA failures in the three groups of cases, nonetheless, the Cs-131 had the fewest. Conclusions One attractive option for men with early-stage prostate cancer is interstitial brachytherapy. The use of the shorter-acting Cs-131 isotope may be expected to have dose-related side effects that resolve more rapidly. This series suggests a trend for improved PSA control outcomes for Cs-131 patients compared with I-125 and Pd-103.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Journal: Salvage Resection and Intracranial Cesium-131 Brachytherapy for Brain Tumors. (Pubmed Central) - Oct 29, 2021
The use of the shorter-acting Cs-131 isotope may be expected to have dose-related side effects that resolve more rapidly. This series suggests a trend for improved PSA control outcomes for Cs-131 patients compared with I-125 and Pd-103. Cesium-131 brachytherapy in this heavily pre-treated cohort resulted in good local control and an acceptable rate of symptomatic adverse radiation effect and toxicity and may be a reasonable treatment option for this select population.
- | Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Journal: Intraprostatic calcification and biochemical recurrence in men treated with cesium-131 prostate brachytherapy. (Pubmed Central) - Oct 13, 2021
Cesium-131 brachytherapy in this heavily pre-treated cohort resulted in good local control and an acceptable rate of symptomatic adverse radiation effect and toxicity and may be a reasonable treatment option for this select population. In a cohort of low- and intermediate-risk prostate cancer patients treated with cesium-131 PB, the rate of BCR in men with baseline IC was low and baseline IC was not associated with a higher risk of BCR.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Long-term outcomes of a prospective randomized trial of Cs/I permanent prostate brachytherapy. (Pubmed Central) - Aug 21, 2021
Short- and long-term urinary, sexual, and bowel quality of life, as well as long-term biochemical control were comparable between I and Cs. This report therefore supports the continued use of Cs as an effective and comparable alternative isotope.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Clinical data, Journal: A matched-pair analysis of clinical outcomes after intracavitary cesium-131 brachytherapy versus stereotactic radiosurgery for resected brain metastases. (Pubmed Central) - Aug 11, 2021
Postresection patients with BM treated with Cs-131 brachytherapy were more likely to achieve local control compared to SRS-treated patients. This study provides preliminary evidence of the potential of Cs-131 to reduce LR following gross-total resection of single BM, with minimal toxicity, and suggests the need for a prospective study to address this question.
- Proxcelan Cesium-131 (cesium-131) / Boston Scientific
[VIRTUAL] Virtual Hands-on Training of Image-guided Urologic Procedures During the COVID-19 Pandemic () - Aug 5, 2021 - Abstract #AUA2021AUA_1216;
While the faculty had more confidence that 30 minutes training was adequate, the attendees requested their own phantom for training. The Covid-19 pandemic provided the opportunity to introduction a novel training approach.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Adjuvant Cesium-131 Brachytherapy for Patients Intolerant of External Beam Radiation Therapy. (Pubmed Central) - Jul 28, 2021
The Covid-19 pandemic provided the opportunity to introduction a novel training approach. No abstract available
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific, Avastin (bevacizumab) / Roche
Clinical, Journal: Cs-131 brachytherapy for patients with recurrent glioblastoma combined with bevacizumab avoids radiation necrosis while maintaining local control. (Pubmed Central) - May 7, 2021
Of interest, there were patients with multiple recurrences whose survival extended beyond 20 months. These findings suggest that the use of highly conformal Cs-131 brachytherapy is a promising treatment for patients with recurrent GBM with minimal risk of development of RN.
- | Enrollment change, Trial withdrawal, Adverse events, Combination therapy: Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer (clinicaltrials.gov) - Apr 19, 2021
P=N/A, N=0, Withdrawn, Sponsor: IsoRay Medical, Inc.
These findings suggest that the use of highly conformal Cs-131 brachytherapy is a promising treatment for patients with recurrent GBM with minimal risk of development of RN. N=100 --> 0 | Enrolling by invitation --> Withdrawn
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal, HEOR: Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR. (Pubmed Central) - Apr 14, 2021
Clinically significant rectal bleeding was <5%. Further followup will confirm if low acute rectal toxicity translates to reduced late toxicity.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Permanent Interstitial Cesium-131 Brachytherapy in Treating High-Risk Recurrent Head and Neck Cancer: A Prospective Pilot Study. (Pubmed Central) - Apr 7, 2021
P1
Most failures were out-of-field or distant. ClinicalTrials.gov, identifier NCT02794675.
- | Enrollment change, Trial withdrawal: A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer (clinicaltrials.gov) - Mar 30, 2021
P=N/A, N=0, Withdrawn, Sponsor: IsoRay Medical, Inc.
ClinicalTrials.gov, identifier NCT02794675. N=40 --> 0 | Recruiting --> Withdrawn
- | Trial completion date, Trial primary completion date: Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer (clinicaltrials.gov) - Feb 15, 2021
P=N/A, N=100, Recruiting, Sponsor: Ronald M. Benoit, MD
N=40 --> 0 | Recruiting --> Withdrawn Trial completion date: Aug 2020 --> Feb 2022 | Trial primary completion date: Aug 2020 --> Feb 2022
- Proxcelan Cesium-131 (cesium-131) / Boston Scientific
[VIRTUAL] Intraprostatic calcification and biochemical recurrence in men treated with Cs-131 prostate brachytherapy. () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_432;
Trial completion date: Aug 2020 --> Feb 2022 | Trial primary completion date: Aug 2020 --> Feb 2022 In a cohort of LR and IR prostate cancer patients treated with Cs-131 PB, the rate of BCR in men with baseline IC was low and baseline IC was not associated with a higher risk of BCR.
- || Proxcelan Cesium-131 (cesium-131) / Boston Scientific
Clinical, Journal: Cesium-131 prostate brachytherapy: A single institutional long-term experience. (Pubmed Central) - Jan 6, 2021
In a cohort of LR and IR prostate cancer patients treated with Cs-131 PB, the rate of BCR in men with baseline IC was low and baseline IC was not associated with a higher risk of BCR. The present study demonstrates that prostate brachytherapy with Cs achieves excellent long-term biochemical control.